The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

Edwards Lifesciences Corp. EW is scheduled to report first-quarter 2025 results on April 23, after the market closes. In the ...

Evaluate the expected performance of Edwards Lifesciences (EW) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key ...

The first-of-its-kind Edwards Lifesciences Sapien M3 TMVR system uses a nitinol dock to anchor the replacement valve in the patient's heart.

Edwards Lifescienes also reported a big increase in pay for the structural heart device developer and manufacturer's median ...

Edwards Lifesciences (NYSE: EW) today announced eight-year data highlighting positive long-term outcomes with its proprietary Resilia tissue.

In a report released on April 15, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Edwards Lifesciences (EW – Research Report), ...

Edwards’ device, dubbed Sapien M3, is the first approved system to use a transfemoral approach to treating mitral ...

Edwards SAPIEN M3 mitral valve replacement system receives CE Mark for transcatheter treatment: Irvine, California Wednesday, ...

Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as ...

Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly ...